IL6 and periodontal disorder: Treating periodontal disease reduces pro-inflammatory mediator levels such as IL-6, tumor necrosis factor-α (TNF-α), CRP, and reactive oxygen species (ROS) and increases pro-resolving lipid mediators, which are anti-inflammatory in nature and help maintain homeostasis.